Debates around tobacco harm reduction are increasingly shaped not only by emerging products and regulatory decisions, but by how science itself is communicated. A recent commentary on misinformation and “clickbait science” in the tobacco harm reduction space highlights a growing concern: that exaggerated claims, selective interpretation of findings, and sensational headlines can distort both public…
The U.S. Food and Drug Administration’s ongoing review of modified risk tobacco product (MRTP) applications for ZYN nicotine pouches represents a pivotal moment in the regulation of non-combustible nicotine. At stake is not whether nicotine products are “safe,” but whether regulators will permit carefully constrained, evidence-based communication about relative risk compared with cigarette smoking. The…
Nicotine pouches remain at the centre of the global harm‑reduction conversation — and a major new peer‑reviewed review helps explain why. A new narrative review by Konstantinos Farsalinos in Internal and Emergency Medicine reinforces a clear message: modern, tobacco‑free nicotine pouches sit at the very lowest end of the toxicant‑exposure continuum. Chemical analyses and biomarker…
Nicotine policy is increasingly being shaped not only by legislators and regulators, but by the channels through which products are made available to adults. In several countries, pharmacies have emerged as a focal point in this debate, acting either as formal gatekeepers of access or as trusted retail environments for smoke-free nicotine products. How pharmacists…
The European Commission has confirmed that the EU Tobacco Policy Expert Group (TPEG) will formally conclude its mandate, even as work on the next revision of the Tobacco Products Directive (TPD) continues. While the end of a technical advisory body may appear procedural, it raises important questions about how expertise, evidence, and stakeholder input will…
As nicotine pouches continue to attract regulatory attention, discussion has increasingly focused on isolated clinical observations and precautionary warnings, often without sufficient context on real-world use patterns or comparative risk. This imbalance risks obscuring a more important question for public health: how nicotine pouches are actually used, by whom, and how regulation can address legitimate…
Nicotine pouches continue to expand across multiple markets, even as regulatory scrutiny intensifies and public debate grows more polarised. This sustained growth is not accidental, nor is it driven by novelty alone. It reflects a convergence of behavioural, commercial, and policy dynamics that are reshaping how adult nicotine users move away from combustible cigarettes. For…
A GINN Insight responding to recent Medscape coverage Nicotine pouches are increasingly positioned at the centre of a familiar policy tension: how to protect young people from nicotine initiation without undermining harm-reduction pathways for adults who smoke. Recent media coverage, including a Medscape Medical News feature, rightly raises youth-protection concerns but risks misrepresenting the evidence…
Nicotine pouches are no longer a niche or experimental category. Retail and market indicators now show sustained growth across major U.S. convenience channels, reinforcing a reality that regulators globally can no longer ignore: consumer uptake is happening faster than policy alignment. Recent U.S. retail reporting highlights accelerating sales, expanding shelf presence, and increasing manufacturer investment…
As nicotine pouches gain visibility in multiple markets, debate around their public-health role is intensifying. A recent peer-reviewed study published in JAMA Network Open adds important empirical clarity to that discussion, particularly around who is using nicotine pouches, why they are using them, and what this means for smoking-related harm. Rather than focusing on speculative…